235 related articles for article (PubMed ID: 21270755)
41. The influence of ATM, ATR, DNA-PK inhibitors on the cytotoxic and genotoxic effects of dibenzo[def,p]chrysene on human hepatocellular cancer cell line HepG2.
Spryszyńska S; Smok-Pieniążek A; Ferlińska M; Roszak J; Nocuń M; Stępnik M
Mutat Res Genet Toxicol Environ Mutagen; 2015 Sep; 791():12-24. PubMed ID: 26338538
[TBL] [Abstract][Full Text] [Related]
42. Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and radiosensitization of a human tumor cell line in vitro.
Griffin RJ; Fontana G; Golding BT; Guiard S; Hardcastle IR; Leahy JJ; Martin N; Richardson C; Rigoreau L; Stockley M; Smith GC
J Med Chem; 2005 Jan; 48(2):569-85. PubMed ID: 15658870
[TBL] [Abstract][Full Text] [Related]
43. DNA-PK inhibition by NU7441 sensitizes breast cancer cells to ionizing radiation and doxorubicin.
Ciszewski WM; Tavecchio M; Dastych J; Curtin NJ
Breast Cancer Res Treat; 2014 Jan; 143(1):47-55. PubMed ID: 24292814
[TBL] [Abstract][Full Text] [Related]
44. Transposon Mutagenesis Reveals Fludarabine Resistance Mechanisms in Chronic Lymphocytic Leukemia.
Pandzic T; Larsson J; He L; Kundu S; Ban K; Akhtar-Ali M; Hellström AR; Schuh A; Clifford R; Blakemore SJ; Strefford JC; Baumann T; Lopez-Guillermo A; Campo E; Ljungström V; Mansouri L; Rosenquist R; Sjöblom T; Hellström M
Clin Cancer Res; 2016 Dec; 22(24):6217-6227. PubMed ID: 26957556
[TBL] [Abstract][Full Text] [Related]
45. Entinostat combined with Fludarabine synergistically enhances the induction of apoptosis in TP53 mutated CLL cells via the HDAC1/HO-1 pathway.
Zhou Z; Fang Q; Li P; Ma D; Zhe N; Ren M; Chen B; He Z; Wang J; Zhong Q; Wang J
Life Sci; 2019 Sep; 232():116583. PubMed ID: 31226417
[TBL] [Abstract][Full Text] [Related]
46. ATR is a caffeine-sensitive, DNA-activated protein kinase with a substrate specificity distinct from DNA-PK.
Hall-Jackson CA; Cross DA; Morrice N; Smythe C
Oncogene; 1999 Nov; 18(48):6707-13. PubMed ID: 10597277
[TBL] [Abstract][Full Text] [Related]
47. LMP-420: a novel purine nucleoside analog with potent cytotoxic effects for CLL cells and minimal toxicity for normal hematopoietic cells.
Mowery YM; Weinberg JB; Kennedy MN; Bond KM; Moore JO; Lanasa MC; Gockerman JP; Diehl LF; Pizzo SV; Cianciolo GJ; Friedman DR
Leukemia; 2010 Sep; 24(9):1580-7. PubMed ID: 20613784
[TBL] [Abstract][Full Text] [Related]
48. Regulation of DNA damage response and cell cycle in radiation-resistant HL60 myeloid leukemia cells.
Hazawa M; Hosokawa Y; Monzen S; Yoshino H; Kashiwakura I
Oncol Rep; 2012 Jul; 28(1):55-61. PubMed ID: 22576796
[TBL] [Abstract][Full Text] [Related]
49. ATM mutations in B-cell chronic lymphocytic leukemia.
Bullrich F; Rasio D; Kitada S; Starostik P; Kipps T; Keating M; Albitar M; Reed JC; Croce CM
Cancer Res; 1999 Jan; 59(1):24-7. PubMed ID: 9892178
[TBL] [Abstract][Full Text] [Related]
50. Identification of dual DNA-PK MDR1 inhibitors for the potentiation of cytotoxic drug activity.
Mould E; Berry P; Jamieson D; Hill C; Cano C; Tan N; Elliott S; Durkacz B; Newell D; Willmore E
Biochem Pharmacol; 2014 Mar; 88(1):58-65. PubMed ID: 24418411
[TBL] [Abstract][Full Text] [Related]
51. Increased transferrin receptor expression following 11q23 deletion as a mechanism of malignant progression in chronic lymphocytic leukemia.
Shackelford RE; Bhalodia AR; Cotelingam JD; Veillon DM; Lowery-Nordberg M
Med Hypotheses; 2006; 66(3):509-12. PubMed ID: 16326028
[TBL] [Abstract][Full Text] [Related]
52. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine.
Yamauchi T; Nowak BJ; Keating MJ; Plunkett W
Clin Cancer Res; 2001 Nov; 7(11):3580-9. PubMed ID: 11705880
[TBL] [Abstract][Full Text] [Related]
53. Chlorambucil cytotoxicity in malignant B lymphocytes is synergistically increased by 2-(morpholin-4-yl)-benzo[h]chomen-4-one (NU7026)-mediated inhibition of DNA double-strand break repair via inhibition of DNA-dependent protein kinase.
Amrein L; Loignon M; Goulet AC; Dunn M; Jean-Claude B; Aloyz R; Panasci L
J Pharmacol Exp Ther; 2007 Jun; 321(3):848-55. PubMed ID: 17351105
[TBL] [Abstract][Full Text] [Related]
54. DNA-activated protein kinase functions in a newly observed S phase checkpoint that links histone mRNA abundance with DNA replication.
Müller B; Blackburn J; Feijoo C; Zhao X; Smythe C
J Cell Biol; 2007 Dec; 179(7):1385-98. PubMed ID: 18158334
[TBL] [Abstract][Full Text] [Related]
55. Regulation of DNA-dependent protein kinase activity in leukemic cells.
Muller C; Salles B
Oncogene; 1997 Nov; 15(19):2343-8. PubMed ID: 9393878
[TBL] [Abstract][Full Text] [Related]
56. Blockade of ataxia telangiectasia mutated sensitizes hepatoma cell lines to sorafenib by interfering with Akt signaling.
Fujimaki S; Matsuda Y; Wakai T; Sanpei A; Kubota M; Takamura M; Yamagiwa S; Yano M; Ohkoshi S; Aoyagi Y
Cancer Lett; 2012 Jun; 319(1):98-108. PubMed ID: 22265862
[TBL] [Abstract][Full Text] [Related]
57. The modulating effect of ATM, ATR, DNA-PK inhibitors on the cytotoxicity and genotoxicity of benzo[a]pyrene in human hepatocellular cancer cell line HepG2.
Stępnik M; Spryszyńska S; Smok-Pieniążek A; Ferlińska M; Roszak J; Nocuń M
Environ Toxicol Pharmacol; 2015 Nov; 40(3):988-96. PubMed ID: 26595742
[TBL] [Abstract][Full Text] [Related]
58. The Hsp90 inhibitor SNX-7081 is synergistic with fludarabine nucleoside via DNA damage and repair mechanisms in human, p53-negative chronic lymphocytic leukemia.
Kaufman KL; Jenkins Y; Alomari M; Mirzaei M; Best OG; Pascovici D; Mactier S; Mulligan SP; Haynes PA; Christopherson RI
Oncotarget; 2015 Dec; 6(38):40981-97. PubMed ID: 26556860
[TBL] [Abstract][Full Text] [Related]
59. In vitro sensitivity of CLL cells to fludarabine may be modulated by the stimulation of Toll-like receptors.
Fonte E; Apollonio B; Scarfò L; Ranghetti P; Fazi C; Ghia P; Caligaris-Cappio F; Muzio M
Clin Cancer Res; 2013 Jan; 19(2):367-79. PubMed ID: 23224401
[TBL] [Abstract][Full Text] [Related]
60. Arsenic trioxide synergistically potentiates the cytotoxic effect of fludarabine in chronic lymphocytic leukemia cells by further inactivating the Akt and ERK signaling pathways.
Lozano-Santos C; Amigo-Jiménez I; Nova-Gurumeta S; Pérez-Sanz N; García-Pardo A; García-Marco JA
Biochem Biophys Res Commun; 2015 May; 461(2):243-8. PubMed ID: 25869069
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
